Drug Trial Radar · NCT06021860
A Phase IV, Two-part, Open-label Study Assessing the Pharmacokinetics, Safety and Pharmacodynamics of Spironolactone Oral Suspension in Pediatric Patients
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Jun 2027
Primary completion
Jun 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- CMP Development, LLCIndustry
- Sponsor type
- Industry
- First posted
- Sep 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-part, 2 periods per part, open-label study with spironolactone oral suspension in pediatric patients with edema due to HF or hepatic cirrhosis. Both study parts will evaluate the safety, PK and PD of multiple doses of spironolactone in patients aged from birth to ≤17 years of age.
Conditions
- Edema Due to Heart Failure or Cirrhosis
Interventions
Spironolactone Oral SuspensionDrug
Spironolactone will be dosed on a mg/kg basis, with actual weight on Day 1 (pre-dose) determining the spironolactone suspension volume administered. Therefore, for a given patient, the dose administered on Day 1, based on the weight measured on Day 1, will be administered throughout their participation in the study. Spironolactone will be administered as a single dose in the single-dose periods (Group 4, Parts 1 and 2), and as QD dosing in the multiple-dose periods (Groups 1 to 4, Parts 1 and 2). The low and high doses to be administered during Part 2 of the study will be determined by the Safety Review Committee following their review of Part 1 data.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Absorption rate constant (Ka) of spironolactone (time^-1) in the multiple-dose periodTime frame: Pre-dose (Day 1) to 22-26 hours post-dose (Day 11)
- Part 2: Absorption rate constant (Ka) of spironolactone (time^-1) in the multiple-dose periodTime frame: Pre-dose (Day 1) to 22-26 hours post-dose (Day 11)
- Part 1: Total clearance from plasma after oral administration (CL/F) of spironolactone in the multiple-dose periodTime frame: Pre-dose (Day 1) to 22-26 hours post-dose (Day 11)
- Part 2: Total clearance from plasma after oral administration (CL/F) of spironolactone in the multiple-dose periodTime frame: Pre-dose (Day 1) to 22-26 hours post-dose (Day 11)
- Part 1: Volume of distribution after oral administration (V/F) of spironolactone in the multiple-dose periodTime frame: Pre-dose (Day 1) to 22-26 hours post-dose (Day 11)
- Part 2: Volume of distribution after oral administration (V/F) of spironolactone in the multiple-dose periodTime frame: Pre-dose (Day 1) to 22-26 hours post-dose (Day 11)
- Part 1: Total clearance from plasma after oral administration (CL/F) of canrenone in the multiple-dose periodTime frame: Pre-dose (Day 1) to 22-26 hours post-dose (Day 11)
- Part 2: Total clearance from plasma after oral administration (CL/F) of canrenone in the multiple-dose periodTime frame: Pre-dose (Day 1) to 22-26 hours post-dose (Day 11)
- Part 1: Volume of distribution after oral administration (V/F) of canrenone in the multiple-dose periodTime frame: Pre-dose (Day 1) to 22-26 hours post-dose (Day 11)
- Part 2: Volume of distribution after oral administration (V/F) of canrenone in the multiple-dose periodTime frame: Pre-dose (Day 1) to 22-26 hours post-dose (Day 11)
- Part 1: Change from baseline in body weight (kg) (Groups 1 through 3)Time frame: Day 1 to Day 18
- Part 1: Change from baseline in body weight (kg) (Group 4)Time frame: Day 1 to Day 26
- Part 2: Change from baseline in body weight (kg) (Groups 1 through 3)Time frame: Day 1 to Day 18
- Part 2: Change from baseline in body weight (kg) (Group 4)Time frame: Day 1 to Day 26
- Part 1: Change from baseline in sodium/potassium (Na/K) ratio (Groups 1 through 3)Time frame: Day -1 to Day 11
- Part 1: Change from baseline in sodium/potassium (Na/K) ratio (Group 4)Time frame: Day 8 to Day 19
- Part 2: Change from baseline in sodium/potassium (Na/K) ratio (Groups 1 through 3)Time frame: Day -1 to Day 11
- Part 2: Change from baseline in sodium/potassium (Na/K) ratio (Group 4)Time frame: Day 8 to Day 19
- Part 1: Change from baseline in fractional excretion of sodium (FENa; %) (Groups 1 through 3)Time frame: Day -1 to Day 11
- Part 1: Change from baseline in fractional excretion of sodium (FENa; %) (Group 4)Time frame: Day 8 to Day 19
- Part 2: Change from baseline in fractional excretion of sodium (FENa; %) (Groups 1 through 3)Time frame: Day -1 to Day 11
- Part 2: Change from baseline in fractional excretion of sodium (FENa; %) (Group 4)Time frame: Day 8 to Day 19
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.